camptothecin has been researched along with belotecan in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 23 (40.35) | 29.6817 |
| 2010's | 30 (52.63) | 24.3611 |
| 2020's | 3 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Ahn, SK; Hong, CI; Jew, SS; Kim, JK; Kim, MY; Lee, JH; Lee, JM; Lee, SJ; Park, JG | 1 |
| Ahn, SK; Bang, YJ; Hong, CI; Kim, JK; Lee, JH; Lee, JM; Lim, KH | 1 |
| Hong, CI; Kim, JH; Lee, SK; Lim, JL; Shin, HJ | 1 |
| Ahn, MR; Choi, HS; Kuh, HJ; Park, IS; Sohn, SJ; Suh, SK; Yang, JS; Yoo, TM | 1 |
| Bae, KS; Cho, JY; Jang, IJ; Seo, HB; Shin, SG; Yi, SY; Yu, KS | 1 |
| Han, SS; Kim, EJ; Kim, JK; Lee, RK; Suh, JE | 1 |
| Crul, M | 1 |
| Chung, MK; Ha, CS; Kim, CY; Kim, JC; Kim, JK; Kim, SH; Lee, HS; Park, SC; Shin, DH; Son, WC; Suh, JE | 1 |
| Chung, MK; Han, SS; Kim, JC | 2 |
| Cha, SW; Cho, KH; Chung, MK; Kang, BH; Kim, HC; Kim, JC; Kim, YB; Park, SC; Park, SH; Shin, DH | 1 |
| Chung, MK; Kim, CY; Kim, JC | 1 |
| Heo, DS; Kim, JS; Kim, NK; Kim, SW; Lee, DH; Lee, JH; Lee, JS; Lee, SJ; Park, K; Ryoo, BY; Suh, C | 1 |
| Bae, KS; Hong, JS; Kang, YK; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Eiseman, JL; Engbers, C; Joseph, E; Parise, RA; Strychor, S; Tonda, ME; Walsh, DR; Yu, NY; Zamboni, BA; Zamboni, WC | 1 |
| Chung, SJ; Kim, DD; Kim, IW; Namkoong, EM; Shim, CK | 1 |
| Bang, YJ; Kang, SB; Kim, JH; Lee, HP; Lee, KH; Nam, JH; Park, SY; Ryu, SY; Seo, SS; Song, YS | 1 |
| Chung, SJ; Han, YH; Jin, HE; Kim, DD; Kim, W; Li, H; Shim, CK | 1 |
| Kim, MJ; Kim, YK; Lee, JH; Myoung, H; Ok, YJ; Yun, PY | 1 |
| Belani, CP; Edwards, RP; Friedland, DM; Maruca, L; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Zamboni, BA; Zamboni, WC | 1 |
| Cho, BK; Kim, CY; Kim, JH; Kim, SK; Kim, YY; Park, CK; Phi, JH; Wang, KC | 1 |
| Choi, MK; Chung, SJ; Jin, QR; Kim, DD; Shim, CK; Shim, WS; Song, IS; Tian, GY; Yang, SG | 1 |
| Belani, CP; Edwards, RP; Friedland, DM; Maruca, L; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Kang, JY; Kim, CH; Kim, HK; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Shim, BY; Song, JS; Yoon, HK | 1 |
| Han, SS; Kang, SB; Kim, HS; Kim, JW; Lee, HP; Park, NH; Seo, SS; Song, YS | 1 |
| Jang, SY; Jung, YW; Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, DW; Nam, EJ | 1 |
| Ahn, JS; Ahn, MJ; Kim, SW; Lee, DH; Lee, JC; Lee, JS; Na, II; Park, K; Ryoo, BY; Suh, C; Yang, SH | 1 |
| Chang, J; Cho, BC; Choi, HJ; Jeong, J; Jung, MK; Kim, JH; Kim, SH; Kim, SK; Lee, YJ; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS | 1 |
| Basse, PH; Donnelly, MK; Eiseman, JL; Joseph, E; Parise, RA; Rice, PM; Shurer, J; Strychor, S; Tonda, ME; Yu, NY; Zamboni, BA; Zamboni, WC | 1 |
| Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Nam, JH | 1 |
| Han, EH; Han, SC; Hwang, IC; Kim, CY; Kim, DG; Kim, YB | 1 |
| Bang, Y; Belani, CP; Edwards, RP; Friedland, DM; Kim, J; Lee, H; Maruca, LJ; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Zamboni, BA; Zamboni, WC | 1 |
| Kang, HH; Kim, CH; Kim, HK; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Rhee, CK; Shim, BY; Song, JS; Sun, DS; Yoon, HK | 1 |
| Bang, YJ; Belani, CP; Edwards, RP; Friedland, DM; Maruca, LJ; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Wu, H; Zamboni, BA; Zamboni, WC | 2 |
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS | 1 |
| Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JH; Lee, JW; Lee, YY; Park, HS; Song, TJ | 1 |
| Cho, EK; Hong, J; Jeong, SH; Jung, M; Kim, YJ; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Shin, DB; Sym, SJ | 1 |
| Beijnen, JH; Caron, WP; Clewell, H; Davis, WL; Dedrick, R; Ramanathan, RK; Schellens, JH; Tonda, M; Yu, N; Zamboni, WC | 1 |
| Cho, BK; Kim, CY; Kim, SK; Lee, SJ; Park, CK; Wang, KC | 1 |
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Ae Kang, Y; Cho, BC; Hong, YK; Jeong, JH; Kim, GM; Kim, JH; Kim, SK; Kim, SM; Kim, YS; Lim, ST; Sung, JH | 1 |
| DeWitt, JP; Han, JH; Kim, B; Kim, CY; Kim, SK; Kim, YH; Lee, JE; Lee, JK; Oh, CW | 1 |
| Chang, J; Cho, BC; Jung, JY; Kim, D; Kim, EY; Kim, GM; Kim, HR; Kim, HS; Kim, JH; Kim, SH; Kim, SK; Kim, YS; Lee, JH; Lim, S; Lim, SM; Park, JS; Park, MS | 1 |
| Kang, HH; Kim, CH; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Shim, BY; Song, JS; Yeo, CD; Yoon, HK | 1 |
| Jin, JY; Lee, GJ; Lee, MY; Min, JW; Seo, MW | 1 |
| Jang, TW; Jeong, JH; Kim, KS; Kim, SY; Kim, YC; Lee, HK; Lee, JE; Lee, KH; Lee, KY; Lee, SY; Oh, IJ; Park, CK; Shin, KC | 1 |
| Choi, HS; Kim, YK; Yun, PY | 1 |
| Kim, JC; Kim, JH; Kim, YM; Yoon, YS | 1 |
| Baik, M; Choi, YJ; Ho, JY; Hur, SY; Ko, M; Lee, H; Lee, S; Lee, SU; Liu, JJ; Park, JY | 1 |
| Hu, J; Huang, X; Liu, Y; Nan, X; Wang, H; Yan, L; Zhang, C | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| An, HJ; Cho, YB; Ghosh, M; Hong, SD; Hur, J; Kang, M; Katuwal, NB; Kim, TH; Moon, YW; Pandey, K; Park, N | 1 |
1 review(s) available for camptothecin and belotecan
| Article | Year |
|---|---|
CKD-602. Chong Kun Dang.
Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drugs, Investigational; Humans; Neoplasms; Technology, Pharmaceutical; Topoisomerase I Inhibitors | 2003 |
22 trial(s) available for camptothecin and belotecan
| Article | Year |
|---|---|
Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome | 2008 |
A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Time Factors; Treatment Outcome | 2007 |
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2008 |
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Topics: Adult; Aged; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2009 |
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Body Composition; Camptothecin; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2009 |
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors | 2010 |
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2009 |
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Topoisomerase I Inhibitors | 2010 |
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Topics: Adolescent; Adult; Age Factors; Aged; Camptothecin; Cell Count; Drug Resistance; Humans; Liposomes; Middle Aged; Monocytes; Mononuclear Phagocyte System; Neoplasms; Neutrophils; Polyethylene Glycols; Topoisomerase I Inhibitors | 2011 |
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Topics: Adult; Aged; Camptothecin; Female; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols; Topoisomerase I Inhibitors | 2012 |
Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Camptothecin; Digestive System; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Incidence; Middle Aged; Neoplasm Recurrence, Local; Nervous System; Respiratory System; Skin; Topoisomerase I Inhibitors; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2011 |
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2012 |
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome | 2012 |
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Computer Simulation; Humans; Injections, Intravenous; Liposomes; Metabolic Clearance Rate; Models, Biological; Monocytes; Neoplasms; Polyethylene Glycols; Tissue Distribution; Topoisomerase I Inhibitors | 2012 |
Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.
Topics: Adult; Aged; Camptothecin; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Small Cell Lung Carcinoma; Young Adult | 2013 |
A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2013 |
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2016 |
34 other study(ies) available for camptothecin and belotecan
| Article | Year |
|---|---|
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Dogs; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors | 1998 |
Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics.
Topics: Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Camptothecin; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Stability; Humidity; Hydrogen-Ion Concentration; Hydrolysis; Solubility; Solvents; Temperature | 2002 |
In vitro pharmacodynamics of CKD-602 in HT-29 cells.
Topics: Camptothecin; Drug Screening Assays, Antitumor; HT29 Cells; Humans | 2002 |
Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Safety pharmacology of CKD-602, a novel anticancer agent.
Topics: Analgesics; Animals; Anticonvulsants; Antineoplastic Agents, Phytogenic; Behavior, Animal; Body Temperature; Camptothecin; Dogs; Enzyme Inhibitors; Gastric Mucosa; Guinea Pigs; Heart; Hemodynamics; Hexobarbital; Hypnotics and Sedatives; Kidney; Mice; Mice, Inbred ICR; Motor Activity; Muscle Contraction; Muscle, Smooth; Pain Measurement; Rats; Rats, Sprague-Dawley; Respiratory Mechanics; Seizures; Sleep; Topoisomerase I Inhibitors | 2003 |
Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cell Count; Body Weight; Camptothecin; Drinking; Eating; Eye Diseases; Female; Injections, Intravenous; Male; Organ Size; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Urinalysis | 2004 |
Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Embryo Loss; Female; Fetal Resorption; Injections, Intravenous; Litter Size; No-Observed-Adverse-Effect Level; Pregnancy; Rabbits; Teratogens; Topoisomerase I Inhibitors | 2005 |
4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cells; Blood Chemical Analysis; Body Weight; Bone Marrow; Camptothecin; Dogs; Dose-Response Relationship, Drug; Drinking; Eating; Female; Hemoglobins; Injections, Intravenous; Lymph Nodes; Male; No-Observed-Adverse-Effect Level; Organ Size; Random Allocation; Spleen; Thymus Gland; Urinalysis | 2005 |
Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Body Weight; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Embryonic Development; Female; Fertility; Injections, Intravenous; Litter Size; Male; No-Observed-Adverse-Effect Level; Organ Size; Rats; Rats, Sprague-Dawley | 2006 |
Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Antineoplastic Agents; Behavior, Animal; Body Weight; Camptothecin; Dose-Response Relationship, Drug; Eating; Embryonic Development; Female; Fetal Development; Injections, Intravenous; Lactation; Longevity; Male; Maternal Exposure; No-Observed-Adverse-Effect Level; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Teratogens | 2007 |
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Extracellular Fluid; Female; Humans; Liposomes; Melanoma; Mice; Mice, SCID; Microdialysis; Polyethylene Glycols; Tissue Distribution; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |
Effect of probenecid on the biliary excretion of belotecan.
Topics: Animals; Bile; Biological Transport; Caco-2 Cells; Camptothecin; Humans; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Probenecid; Rats | 2007 |
Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Camptothecin; Dogs; Humans; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Rats; Rats, Sprague-Dawley; Topotecan | 2008 |
Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Mouth Mucosa; Mouth Neoplasms; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Submandibular Gland Neoplasms; Tongue Neoplasms; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2009 |
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glioblastoma; Humans; Inhibitory Concentration 50; Time Factors; Topoisomerase I Inhibitors | 2009 |
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.
Topics: Acridines; Acute Kidney Injury; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Calcium Channel Blockers; Camptothecin; Down-Regulation; Folic Acid; Glomerular Filtration Rate; Indicators and Reagents; Kidney; Male; Organic Anion Transport Protein 1; p-Aminohippuric Acid; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines; Verapamil; Vitamin B Complex | 2009 |
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan | 2010 |
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
Topics: Animals; Area Under Curve; Camptothecin; Chromatography, Liquid; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Mass Spectrometry; Mice; Mononuclear Phagocyte System; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2010 |
Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dogs; Dose-Response Relationship, Drug; Infusions, Intravenous; Injections, Intravenous; Male; Severity of Illness Index | 2010 |
Allometric scaling of pegylated liposomal anticancer drugs.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Dogs; Doxorubicin; Female; Humans; Liposomes; Male; Mice; Models, Theoretical; Neoplasms; Polyethylene Glycols; Rats; Software; Species Specificity; Time Factors | 2011 |
Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2012 |
Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topoisomerase I Inhibitors | 2012 |
Combination therapy of cilengitide with belotecan against experimental glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Snake Venoms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Peritoneum; Topoisomerase I Inhibitors; Treatment Outcome | 2014 |
The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Epithelial Cells; Humans; Mouth Neoplasms; Tumor Suppressor Protein p53 | 2019 |
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan | 2019 |
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Development of an enzyme‑linked immunosorbent assay for camptothecin.
Topics: Animals; Antibodies, Monoclonal; Binding, Competitive; Camptothecin; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Female; Haptens; Hemocyanins; Humans; Immune Sera; Limit of Detection; Mice; Mice, Inbred BALB C; Protein Binding; Topotecan | 2019 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphorylation; Pyrimidines; Sulfonamides; Sulfoxides; Xenograft Model Antitumor Assays | 2021 |